Investing in the Next Generation Dermal Delivery
Why are we raising capital?
EncapSolutions is raising to accelerate the commercial rollout of the SkinSync® transdermal delivery platform — the technology that makes our patches work differently from anything else on the market.
The capital funds three specific outcomes: GMP certification of our Australian manufacturing facility, scaling our U.S. direct-to-consumer channel, and formalising the pharmaceutical co-development partnerships that represent the next phase of the platform's value.
This is not a startup searching for a business model. The platform works, the products are live, and the capital we are raising now is the bridge between early commercial validation and institutional-scale growth.
Why Encapsolutions?
SkinSync® is a proprietary nanofibre transdermal delivery platform developed in Sydney. Our electrospinning process encapsulates active compounds within an ultrafine polymer matrix — engineered to dissolve at the skin surface at a controlled rate, maximising delivery of every milligram of active ingredient.
Independent performance testing demonstrates up to 30x greater active delivery compared to conventional transdermal patch formats. Our first commercial product range — SkinSync® Patches — is live in the U.S. market. Patent applications covering the core platform technology have been filed across key international jurisdictions.
The platform is designed from the outset for two markets: consumer natural health (our current commercial stage) and pharmaceutical co-development (the next stage).
Why Now?
Three things are converging:
First, our GMP-capable cleanroom facility in Sydney is operational. The capital raised now completes the certification that unlocks pharmaceutical-grade manufacturing — the prerequisite for every licensing and co-development conversation we are having.
Second, our U.S. commercial channel is live and generating early data. Shopify is active. Our Amazon Brand Store launches July 2026. Paid acquisition commenced June 2026. The commercial thesis is being tested in real time.
Third, pharma co-development discussions are underway. The window to enter this raise at the current valuation closes when those discussions formalise. Investors who enter now participate in both commercial stages.
The Raise — Broad Terms
EncapSolutions is raising AUD $3,000,000 via Convertible Note.
This raise is open exclusively to wholesale investors (Australia), accredited investors (United States), and equivalent sophisticated investor classifications in other jurisdictions.
Full terms, documentation, and deal room access are provided to qualified enquirers following execution of a Non-Disclosure Agreement.
Request Investor Information
If you are a wholesale or accredited investor and would like to receive the full investor information package — including the pitch deck, financial projections, FAQ, and deal terms — please register your interest below.
We respond to all enquiries within 48 hours.
This page contains general information only. It does not constitute a securities offering, financial product advice, or an invitation to invest. Investment in EncapSolutions Pty Ltd is available to wholesale investors under s.708 of the Australian Corporations Act 2001, accredited investors under SEC Regulation D, and equivalent classifications in other jurisdictions. Full documentation is provided upon execution of a Non-Disclosure Agreement.
Why Patches?
The transdermal patch market is worth over USD $7 billion globally — and it is growing, driven by demand for drug delivery formats that bypass the digestive system, reduce dosing frequency, and improve patient compliance.
The problem is that conventional patch technology wastes the majority of its active load. Inconsistent release rates, poor absorption efficiency, and high active ingredient wastage have constrained the category's potential for decades.
The market is not waiting for a new product. It is waiting for a better delivery architecture.